Rocket Lab stock pops 25% after company reports strong revenue growth, first Neutron deal

Rocket Lab stock pops 25% after company reports strong revenue growth, first Neutron deal


Rocket Lab shares jumped in post-market trading after the company reported third-quarter results and announced its first customer for its coming Neutron vehicle.

The space infrastructure company reported third-quarter revenue increased to $104.8 million, up 55% from $67.6 million for the same period a year ago. Its net loss also increased year-over-year, to $51.9 million from $40.6 million.

Rocket Lab forecast fourth-quarter revenue between $125 million and $135 million, which at the midpoint would see the company bring in about $430 million this year.

Additionally, the company announced its first launch deal for its Neutron rocket.

A “confidential commercial satellite constellation operator” signed for two missions in mid-2026, which Rocket Lab says were at a price “consistent with our target” for the vehicle. Previously, the company said it was targeting a price point of about $50 million per Neutron launch.

Shares of Rocket Lab jumped as much as 25% in after-hours trading, up from its close at $14.66 a share.

Read more CNBC space news



Source

Forgotten no more: Generation X is driving beauty sales
Business

Forgotten no more: Generation X is driving beauty sales

Ryan Mckeever | E+ | Getty Images Move over, Sephora kids. While younger generations have been buying beauty products in droves, data shows that a different generation holds more spending power: Generation X. Often dubbed the “forgotten generation,” Gen X spans those born between 1965 and 1980, according to Pew Research Center. Sandwiched between baby […]

Read More
FDA fast-tracks psychedelic drug research following Trump executive order
Business

FDA fast-tracks psychedelic drug research following Trump executive order

FILE PHOTO: Psilocybin or “magic mushrooms” are seen in an undated photo provided by the U.S. Drug Enforcement Agency (DEA) in Washington, U.S. May 7, 2019. DEA | Reuters The U.S. Food and Drug Administration on Friday announced a series of measures aimed at accelerating the development of psychedelic treatments for serious mental illness. That […]

Read More
New York’s pied-a-terre tax sets up legal fight over values
Business

New York’s pied-a-terre tax sets up legal fight over values

A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox. New York’s proposed tax on second homes worth more than $5 million is likely to spark costly legal battles over how to value […]

Read More